title: [Survival analysis for different molecular subtypes of breast cancers after treatment].
abstract: OBJECTIVE
  To explore the survival status after treatment for patients with different molecular subtypes of breast cancers.
  
  
  METHODS
  A total of 4491 patients with invasive breast cancer from January 2000 to July 2011 were retrospectively recruited to receive pathological verification and treatment at our clinic. According to the immunohistochemical results of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2), they were assigned into 3 groups of HR+/HER2-, HER2+ and HR-/ HER2-. Survival analyses were conducted to examine the effects of molecular subtypes and lymph node status on survival.
  
  
  RESULTS
  The 3-year recurrence free survival for HR+/HER2-, HER2+ and HR-/HER2- were 94.9%, 89.5% ane 92.3% respectively. Different molecular subtypes presented different survival patterns (P = 0.0001). The 3-year recurrence-free survival (RFS) for LN+ and LN- was 87.1% and 97.8% respectively. And statistical difference existed (P < 0.01). No difference was detected among three molecular subtypes of LN- (P = 0.102); However, for LN+ patients, HR+/HER2- showed a higher RFS than HER2+ and HR-/HER2 (P = 0.001).
  
  
  CONCLUSIONS
  Different molecular subtypes of breast cancers have varying survival. And lymph node status is probably an important prognostic factor.
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Ying-jian
authors.initials: YJ
authors.lastname: He
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Jin-feng
authors.initials: JF
authors.lastname: Li
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Tian-feng
authors.initials: TF
authors.lastname: Wang
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yun-tao
authors.initials: YT
authors.lastname: Xie
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Zhao-qing
authors.initials: ZQ
authors.lastname: Fan
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Li-ze
authors.initials: LZ
authors.lastname: Wang
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Min
authors.initials: M
authors.lastname: Ying
authors.affiliation: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: ouyanghongtao@263.net.
authors.forename: Tao
authors.initials: T
authors.lastname: Ouyang
mesh_terms: D001943:Breast Neoplasms / Q000145:classification / Q000401:mortality* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human